Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075782 | 0.96 | LTA4H (0.78) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15480394 | 0.92 | LTA4H (0.76) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL21067844 | 0.92 | LTA4H (1.00) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15480412 | 0.90 | LTA4H (0.74) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL21067416 | 0.86 | LTA4H (1.00) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL7364137 | 0.86 | HDAC3 (0.74) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2170643 | 0.85 | LTA4H (0.76) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL5659338 | 0.85 | LTA4H (0.76) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL7932279 | 0.85 | LTA4H (0.76) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3224230 | 0.85 | LTA4H (0.76) | LTA4HMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | LTA4H 2104/4885MEN1 713/4885KMT2A 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.